At a glance
- Originator Unknown
- Developer Kureha Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jun 1998 Discontinued-II for Cancer in Japan (Unknown route)
- 10 Dec 1993 Phase-II clinical trials for Cancer in Japan (Unknown route)